Elizabeth is a Study Director of Oncology at Charles River's Discovery Research site in Morrisville, North Carolina. She joined the company in 2018. She has over 25 years of experience in the life science industry, with the last 15 spent in various roles of scientific leadership for biotech companies and academic groups. She earned her PhD from Clemson University, Clemson, SC, where her work focused on modulation of the immune response. She did her post-doctorate work at UNC-Chapel Hill where she studied autoimmunity and defined the role of B-1 B cells. After joining the faculty at UNC she went on to become Director of Immunology at Alphavax, Inc. where she lead and performed the pre-clinical and clinical immune monitoring for alphavirus vaccines for HIV, cancer, CMV and influenza. She went on to Duke University and continued her immune monitoring role in the Department of Neurosurgery specializing in immunotherapy of brain tumors. She led the pre-clinical and clinical immune monitoring of trials to combat glioblastoma. Her peer-review studies have appeared in Nature, PNAS, Journal of Experimental Medicine, Journal of Immunology and Cancer Research.